Nioside®
Nintedanib
Therapeutic action
Antineoplastic – Protein tyrosine kinase inhibitor.
Indications
- Treatment of idiopathic pulmonary fibrosis (IPF) in adults.
- Treatment of other chronic fibrosing interstitial lung diseases (PF-ILD) with a progressive phenotype.
- Slowing the rate of lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SS-ILD).
Presentation
Softgel capsules of 100 mg. and 150 mg.